Does Cardarine Actually Cause Cancer?

Cardarine sits in a strange position in the performance world, somewhere between a legitimate metabolic tool and one of the most abandoned drug candidates in recent pharmaceutical history, and understanding why requires understanding what it actually does inside your cells.

Your cells contain receptors that act like switches, and when the right molecule binds to them, they turn on specific sets of genes. Cardarine binds to something called PPARdelta, which is a receptor that controls genes involved in fat oxidation and mitochondrial growth. When PPARdelta gets activated, your body shifts its fuel preference toward fat, builds more mitochondria, and improves endurance capacity. This is why cardarine became attractive to athletes and researchers alike. The metabolic effects are real. GlaxoSmithKline ran actual human trials with it, including a randomized controlled trial of 268 subjects taking up to 10 milligrams per day for 12 weeks, and they saw no serious adverse events. That part of the story is accurate.

But GSK shut the program down, and the reason they did that is the part most people either don't know or actively misrepresent.

In 2007, GSK ran the standard two-year carcinogenicity studies that pharmaceutical companies are required to do before bringing a drug to market. They ran it in Han Wistar rats and separately in mice, and what they found was not a single tumor in one organ at a high dose. It was tumors across multiple organ systems, including the liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs, in both species, at every dose level they tested. The multi-species confirmation matters because when you see a carcinogenic signal in rats, it might reflect something specific to rat biology. When you see the same signal in mice, it becomes much harder to dismiss as a species artifact.

The dose question is where most of the online debate lives, and it deserves an honest look.

When researchers convert animal doses to human equivalents, the standard method recommended by the FDA uses body surface area rather than simple body weight, because surface area scales more accurately to how drugs move through mammalian physiology. When you run that conversion on the lowest dose that produced tumors in female rats, you get approximately 39 milligrams per day for a 175-pound person. For males it comes out to around 64 milligrams per day. People using cardarine recreationally are typically taking 10 to 20 milligrams. So yes, there is a gap.

But context matters for what that gap means. In pharmaceutical development, the accepted safety buffer between the lowest dose that causes harm in animals and the dose given to humans is ten times. The gap between 10 milligrams and 39 milligrams is roughly four times. The gap between 20 milligrams and 39 milligrams is less than two times. And critically, the researchers never found a dose low enough that tumors did not appear. There was no clean threshold. Every dose they tested produced the tumor signal, which means they could not establish what pharmacologists call a no-observed-adverse-effect level, the dose below which you can say with confidence that the drug is not doing this. Without that floor, you cannot calculate a safe margin, because you do not know where the risk actually stops.

This is why the drug was killed, not because the doses were unreasonably high, but because the dose-response curve never bottomed out.

Now there is a layer of biology here that makes this more complicated, and it is the part the video touched on that deserves more depth.

Exercise also activates PPARdelta. In fact, a significant part of the mitochondrial and fat-burning adaptation you get from endurance training runs through this exact receptor. So if cardarine's mechanism involves PPARdelta activation, and exercise also activates PPARdelta, why don't runners get multi-organ tumors?

The answer appears to involve something called AMPK, which is short for AMP-activated protein kinase, a molecule your body produces during energy stress, meaning hard physical effort. AMPK acts as a cellular energy sensor, and when it is active, it does something specific to PPARdelta: it phosphorylates it at a site called serine 50, which suppresses the pro-tumorigenic gene programs that PPARdelta can drive while leaving the metabolic benefits intact. Research published in the Journal of Biological Chemistry in 2021 identified this mechanism directly. Exercise activates both PPARdelta and the molecular brake that keeps PPARdelta from running the programs that promote tumor growth.

Cardarine activates PPARdelta without reliably triggering that same AMPK-driven suppression. You get the gas pedal without the governor. Whether that difference is what produced the tumor signal in the animal studies is still theoretical, but the mechanism is biologically coherent and the finding has been replicated in laboratory models.

What does not exist is a study that tests cardarine at 10 to 20 milligrams per day, in healthy humans, over a period long enough to observe cancer outcomes, with cancer as an actual endpoint. The 12-week human trial was far too short to detect carcinogenicity. No equivalent of a two-year study has ever been run in people because no pharmaceutical company will fund a drug they already abandoned, and no ethics board would approve exposing healthy subjects to a compound with this animal profile just to see what happens.

That absence of data is not the same as absence of risk. It means the risk is unknown at the doses people are actually using, and unknown is not the same as safe.

The honest frame for this compound is that you are not choosing between proven danger and proven safety. You are choosing between a known animal carcinogenicity signal with multi-organ involvement across two species, no established safe dose in any species, a mechanistic explanation for why the pharmacological activation differs from the physiological activation, and a data gap at human recreational doses that will likely never be filled. Anyone presenting this as obviously fine because the doses were high is ignoring that the lowest tested dose produced the same outcome as the highest, and that no safe threshold was ever found.

The biology of cardarine is genuinely interesting. The receptor it works on is real, the metabolic effects are real, and the mechanism through which exercise produces similar benefits without apparent cancer risk is real. But exercise earns those benefits through a system that includes its own brakes, and cardarine does not come with the brakes included.

---

References

1. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ 2009. Rat two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting, Abstract #895. Multi-organ tumors at all dose levels in Han Wistar rats including liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. Source
2. Newsholme SJ, Dunsford WS, et al. 2009. Mouse two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting. Multi-organ tumor signal confirmed in mice, consistent with rat findings. Source
3. Ding Y, et al. 2021. AMPK phosphorylates PPARdelta at Serine 50, suppressing pro-tumorigenic transcriptional programs while preserving metabolic benefits. Journal of Biological Chemistry, 297:100954. Source
4. Reagan-Shaw S, Nihal M, Ahmad N 2008. Dose translation from animal to human studies revisited. FASEB Journal, 223:659-661. FDA-preferred body surface area normalization method for interspecies dose conversion. Source
5. Olson EJ, Pearce GL, Jones NP, Sprecher DL 2012. Human RCT, 268 subjects, up to 10 mg/day for 12 weeks. No serious adverse events but far too short for cancer assessment. Arteriosclerosis, Thrombosis, and Vascular Biology, 329:2289-2294. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness